Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery

被引:26
作者
Alsarra, Ibrahim A. [1 ]
机构
[1] King Saud Univ, Dept Pharmaceut, Coll Pharm, Riyadh 11451, Saudi Arabia
关键词
Niosomes; proniosomes; piroxicam; transdermal delivery; permeation; IN-VIVO EVALUATION; PERCUTANEOUS-ABSORPTION; VESICLES NIOSOMES; SKIN PERMEATION; DRUG CARRIER; VITRO; LIPOSOMES; SURFACTANT; SYSTEM; CYCLODEXTRIN;
D O I
10.1080/02652040802305618
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The current investigation aims to evaluate the transdermal potential of niosomes bearing a potent non-steroidal anti-inflammatory, piroxicam. Piroxicam-loaded niosomes were prepared and characterized for surface morphology, entrapment efficiency and in vitro permeation across excised rat skin from various proniosome gel formulations using Franz diffusion cells. Various non-ionic surfactants were used to achieve optimum encapsulation efficiency. The prepared proniosomes significantly improved drug permeation and reduced the lag time (p < 0.05). Proniosomes prepared with Span 60 provided a higher piroxicam flux across the skin than did those prepared with Tween 80. Niosomes prepared using Span 60 showed a higher release rate than those prepared using non-ionic surfactants, Span 20 and Span 80, while those prepared from Tween showed higher release rate than formula prepared with Span. This indicates that lipophilicity and hydrophilicity of surfactant has a main role in release rates of piroxicam. Particle size of piroxicam niosomal vesicles formed by proniosome was determined by scanning electron microscopy. The encapsulation efficiency was evaluated by a specific high performance liquid chromatography method. Niosomes formed from using Spans and Tweens exhibited very high encapsulation efficiency. The results are very encouraging and suggest that niosomes can act as promising carriers offering an alternative approach for transdermal delivery of piroxicam.
引用
收藏
页码:272 / 278
页数:7
相关论文
共 39 条
[1]   Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol [J].
Agarwal, R ;
Katare, OP ;
Vyas, SP .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 228 (1-2) :43-52
[2]   Proniosomes as a drug carrier for transdermal delivery of ketorolac [J].
Alsarra, IA ;
Bosela, AA ;
Ahmed, SM ;
Mahrous, GM .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2005, 59 (03) :485-490
[3]   THE PREPARATION AND PROPERTIES OF NIOSOMES NON-IONIC SURFACTANT VESICLES [J].
BAILLIE, AJ ;
FLORENCE, AT ;
HUME, LR ;
MUIRHEAD, GT ;
ROGERSON, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1985, 37 (12) :863-868
[4]   Novel mechanisms and devices to enable successful transdermal drug delivery [J].
Barry, BW .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (02) :101-114
[5]   Maltodextrin-based proniosomes [J].
Blazek-Welsh, AI ;
Rhodes, DG .
AAPS PHARMSCI, 2001, 3 (01) :art. no.-1
[6]   Piroxicam encapsulated in liposomes: Characterization and in vivo evaluation of topical anti-inflammatory effect [J].
Canto, GS ;
Dalmora, SL ;
Oliveira, AG .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (12) :1235-1239
[7]   LOGICS OF TRANSDERMAL CONTROLLED DRUG ADMINISTRATION [J].
CHIEN, YW .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1983, 9 (04) :497-520
[8]   DEVELOPMENT OF A DYNAMIC SKIN PERMEATION SYSTEM FOR LONG-TERM PERMEATION STUDIES [J].
CHIEN, YW ;
VALIA, KH .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1984, 10 (04) :575-599
[9]   Liposomes and niosomes as topical drug delivery systems [J].
Choi, MJ ;
Maibach, HI .
SKIN PHARMACOLOGY AND PHYSIOLOGY, 2005, 18 (05) :209-219
[10]   In vitro and in vivo percutaneous absorption of topical dosage forms:: case studies [J].
Csóka, I ;
Csányi, E ;
Zapantis, G ;
Nagy, E ;
Fehér-Kiss, A ;
Horváth, G ;
Blazsó, G ;
Eros, I .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 291 (1-2) :11-19